Celgene gets rights to Epizyme’s personalized cancer therapeutics
Celgene Corp. will work with epigenetics company Epizyme Inc. to discover, develop, and sell new personalized cancer therapeutics based on Epizyme’s work with histone methyltransferase (HMT) inhibitors for genetically defined cancers.
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.